New York’s OverT Bio, a pioneering biotech firm focused on the creation of effective and secure cellular therapies for solid tumors, has proudly declared its receipt of a $120,000 G-Rex Grant. This funding comes from ScaleReady, in partnership with Wilson Wolf Manufacturing, along with Bio-Techne Corporation and CellReady.
This grant is set to bolster OverT Bio’s continuous efforts to develop next-gen cell therapies for solid tumors, rooted in their innovative OverTarget and OverTCR discovery platforms.
ScaleReady’s $20 million grant initiative, which encompasses the G-Rex Grant, aims to drive forward cell and gene therapy (CGT) development and production. It offers considerable free-of-charge assistance, permitting swift optimization of cell manufacturing techniques.
“We’re thrilled to have ScaleReady’s backing and acknowledgment of our technology’s potential to contribute substantially to our united goal of introducing new life-saving treatments for cancer patients,” said Mat Legut from OverT Bio. “The grant, along with access to cutting-edge GMP closed system products and ScaleReady’s know-how, will advance our product development in ways that secure future scalability and cost-effectiveness of these therapeutic options.”
Josh Ludwig, ScaleReady’s commercial director, commented, “Our support for OverT Bio exemplifies how the G-Rex Grant Programme facilitates progress in the sphere of cell and gene-modified cell therapy. It underpins ScaleReady’s core aim of equipping every CGT company to economize on time and funds while establishing a robust value proposition for further investment.”
Utilizing revolutionary pooled functional screening and synthetic genomics platforms (OverTarget and OverTCR), OverT Bio is identifying novel therapeutic targets and genetic enhancements in a data-centric, unbiased fashion, promising groundbreaking treatments for cancer patients not adequately served by existing care standards.
ScaleReady delivers a G-Rex-focused manufacturing framework to the domain of cell and gene-modified cell therapy (CGT), offering one of the most pragmatic, adaptable, scalable, and cost-effective CGT drug product development and manufacturing solutions available. The G-Rex production platform is currently in use by more than 800 entities, producing drug products for about half of CGT clinical trials and five commercial CGT drugs.
Organizations that benefit from ScaleReady’s comprehensive expertise can alleviate years of time lost and save millions of dollars in the journey toward CGT commercialization.
Wilson Wolf Manufacturing is committed to easing CGT therapy research, process development, and manufacturing, achieved through its worldwide scalable G-Rex technology applied in various CGT applications, from basic research to commercial drug creation—promoting hope for cancer patients, one G-Rex device at a time.